Onset of abnormal blood and lymphatic vessel function and interstitial hypertension in early stages of carcinogenesis

Cancer Research

Volumn 66, Issue 7, 2006, Pages 3360-3364

  Hagendoorn, Jeroen ^a   Tong, Ricky ^a   Fukumura, Dai ^a   Lin, Qingcong ^b   Lobo, Jennifer ^a   Padera, Timothy P ^a   Xu, Lei ^a   Kucherlapati, Raju ^b   Jain, Rakesh K ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b LABORATORY FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; DNA POLYMERASE;

ANIMAL TISSUE; ARTICLE; CANCER DIAGNOSIS; CARCINOGENESIS; CONTROLLED STUDY; HYPERTENSION; IRRADIATION; LYMPH VESSEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE PRESSURE; ULTRAVIOLET B RADIATION; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; CELL TRANSFORMATION, NEOPLASTIC; DNA-DIRECTED DNA POLYMERASE; EXTRACELLULAR FLUID; HYDROSTATIC PRESSURE; HYPERPLASIA; LYMPHATIC VESSELS; MICE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 33645738314     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-2655     Document Type: Article

References (22)

1. Gullino PM. Angiogenesis and oncogenesis. J Natl Cancer Inst 1978;61:639-43.
2. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
3. Jain RK, Fenton BT. Intratumoral lymphatic vessels: a case of mistaken identity or malfunction? J Natl Cancer Inst 2002;94:417-21.
4. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307:58-62.
5. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003;9:685-93.
6. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels. Nature 2004;427:695.
7. Bergers G, Hanahan D, Coussens LM. Angiogenesis and apoptosis are cellular parameters of neoplastic progression in transgenic mouse models of tumorigenesis. Int J Dev Biol 1998;42:995-1002.
8. Herzig M, Christofori G. Recent advances in cancer research: mouse models of tumorigenesis. Biochim Biophys Acta 2002;1602:97-113.
9. Lin Q, Clark AB, McCulloch SD, et al. Increased susceptibility to ultraviolet-induced skin carcinogenesis in Pol η-deficient mice. Cancer Res 2006;66:87-94.
10. Boucher Y, Kirkwood JM, Opacic D, Desantis M, Jain RK. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991;51:6691-4.
11. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002;296:1883-6.
12. Yuan F, Leunig M, Berk DA, Jain RK. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc Res 1993;45:269-89.
13. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
14. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell 2002;108:135-44.
15. Blankenstein T. The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol 2005;17:180-6.
16. Coussens LM, Tinkle CL, Hanahan D, Werb Z. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000;103:481-90.
17. Isaka N, Padera TP, Hagendoorn J, Fukumura D, Jain RK. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res 2004;64:4400-4.
18. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998;4:655-7.
19. Boucher Y, Leunig M, Jain RK. Tumor angiogenesis and interstitial hypertension. Cancer Res 1996;56:4264-6.
20. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
21. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-7.
22. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3:24-40.